1S70 Stock Overview
A clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cartesian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.20 |
| 52 Week High | US$39.00 |
| 52 Week Low | US$13.37 |
| Beta | 0 |
| 11 Month Change | -19.80% |
| 3 Month Change | n/a |
| 1 Year Change | -58.46% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1S70 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.9% | -0.7% | 0.2% |
| 1Y | -58.5% | -17.2% | 8.5% |
Return vs Industry: 1S70 underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 1S70 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 1S70 volatility | |
|---|---|
| 1S70 Average Weekly Movement | 18.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 1S70's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1S70's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 38 | Carsten Brunn | www.cartesiantherapeutics.com |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases.
Cartesian Therapeutics, Inc. Fundamentals Summary
| 1S70 fundamental statistics | |
|---|---|
| Market cap | €460.54m |
| Earnings (TTM) | -€271.17m |
| Revenue (TTM) | €46.03m |
10.0x
P/S Ratio-1.7x
P/E RatioIs 1S70 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1S70 income statement (TTM) | |
|---|---|
| Revenue | US$47.94m |
| Cost of Revenue | US$49.83m |
| Gross Profit | -US$1.89m |
| Other Expenses | US$280.49m |
| Earnings | -US$282.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.11 |
| Gross Margin | -3.95% |
| Net Profit Margin | -589.05% |
| Debt/Equity Ratio | 0% |
How did 1S70 perform over the long term?
See historical performance and comparison